The proposed bill establishes the Washington medical use of psilocybin program, recognizing its therapeutic potential for treating serious and treatment-resistant conditions. It outlines the roles of clinicians, producers, and qualified patients, emphasizing the need for training standards and oversight by the Department of Health. Participants in the program are protected from arrest or prosecution if they adhere to established guidelines. The bill also mandates licensing requirements for producers and clinicians, including necessary training and compliance with safety protocols, while maintaining accurate records and establishing a secure electronic registry for tracking treatments.

Additionally, the bill amends existing definitions related to cannabis and controlled substances, clarifying that "cannabis products" include any product containing THC while excluding cannabis health and beauty aids and FDA-approved products. It introduces the term "cannabis researcher" and specifies that "controlled substances" do not include hemp or industrial hemp, adding psilocybin for medical purposes to the list of exceptions. The bill emphasizes social equity plans for cannabis licensees and outlines definitions for various cannabis-related terms. It also includes provisions for implementation and expiration, stating the act will take effect on July 1, 2028, with certain sections expiring on June 30, 2027, while ensuring the enforceability of remaining provisions if any part is deemed invalid.

Statutes affected:
Original bill: 69.50.101